Gene disorders and molecular genetic subtypes of malignant gliomas

Close metadata

Recommended articles:

Patients with long-term survival in malignant gliomas after photodynamic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):54-61

Malignant brain tumors are noteworthy for a lot of genetic disorders that show itself as decreased or increased gene function of different genes and lead to tumor development. The differences in the molecular genetic profile can identify several subtypes of malignant gliomas, which are distinguished by both their clinical course and susceptibility to drugs. This can be the basis for developing individualized therapy options in patients with malignant gliomas.

Keywords:

malignant gliomas

gene disorders

molecular genetic subtypes

malignant gliomas

gene disorders

molecular genetic subtypes

Authors:

Borisov K.E.

GUZ "Respublikanskiĭ klinicheskiĭ onkologicheskiĭ dispanser" Minzdrava Respubliki Bashkortostan, Ufa

Sakaeva D.D.

GBUZ "Bashkirskiĭ respublikanskiĭ klinicheskiĭ onkologicheskiĭ dispanser", Ufa

List of references:

Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005; 64 (6): 479-89.
Kanu O.O., Hughes B., Di C. et al. Glioblastoma multiforme oncogenomics and signaling pathways. Clin. Med. Oncol. 2009; 3: 39-52.
Jones T.S., Holland E.C. Molecular pathogenesis of malignant glial tumors. Toxicol. Pathol. 2011; 39 (1): 158-66.
Crespo I., Vital A.L., Nieto A.B. et al. Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. J. Mol. Diagnost. 2011; 13 (6): 634-47.
Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 2007; 170 (5): 1445-53.
Ramirez C., Bowman C., Maurage C.A. et al. Loss of 1p, 19q, and 10q heterozogosity prospectively predicts prognosis of oligodendroglial tumors - towards individualized tumor treatment? Neurooncology. 2010; 12 (5): 490-9.
Nakamura M., Ishida E., Shimada K. et al. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab. Invest. 2005; 85 (2): 165-75.
Ruano Y., Mollejo M., Ribalta T. et al. Identification of novel candidate target genes in amplicons of glioblastoma multiforme tumors detected by expression and CGH microarray profiling. Mol. Cancer. 2006; 5: 39.
Frederick L., Wang X.Y., Eley G., James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000; 60 (5): 1383-7.
Wrensch M., Wiencke J.K., Wiemels J. et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Canser Res. 2006; 66: 4531-41.
Batchelor T.T., Betensky R.A., Esposito J.M. et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin. Canser Res. 2004; 10: 228-33.
Brennan C., Momota H., Hambardzumyan D. et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009; 4 (11): e7752.
Shinojima N., Tada K., Shiraishi S. et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003; 63: 6962-70.
Pelloski C.E., Ballman K.V., Furth A.F. et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin. Oncol. 2007; 25 (16): 2288-94.
Puputti M., Tynninen O., Sihto H. et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol. Cancer Res. 2006; 4 (12): 927-34.
Liu K.W., Hu B., Cheng S.Y. Platelet-derived growth factor receptor alpha in glioma: a bad seed. Chinese J. Cancer. 2011; 30 (9): 590-602.
Cichowski K., Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001; 104 (4): 593-604.
Chakravarti F., Zhai G., Suzuki Y. et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 2004; 22: 1926-33.
Jeuken J., van den Broecke C., Gijsen S. et al. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol. 2007; 114 (2): 121-33.
Jacob K., Albrecht S., Sollier C. et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br. J. Cancer. 2009; 101 (4): 722-33.
Schindler G., Capper D., Meyer J. et al. Analysis of BRAF V600E mutation in 1320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121 (3): 397-405.
Nicolaides T.P., Li H., Solomon D.A. et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clin. Cancer Res. 2011; 17 (24): 7595-604.
Hlobilkova A., Ehrmann J., Sedlakova E. et al. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression? Neoplasma. 2007; 54 (4): 334-41.
Holland E.C. et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 2000; 25 (1): 55-7.
Raychaudhuri B., Han Y., Lu T., Vogelbaum M.A. Aberrant constitutive activation of nuclear factor kappa B in glioblastoma multiforme drives invasive phenotype. J. Neurooncol. 2007; 85 (1): 39-47.
Bredel M., Scholtens D.M., Yadav A.K. et al. NFKBIA deletion in glioblastomas. N. Engl. J. Med. 2011; 364 (7): 627-37.
Shaw R.J., Paez J.G., Curto M. et al. The NF2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell. 2001; 1 (1): 63-72.
Ishii N., Maier D., Merlo A. et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999; 9 (3): 469-79.
Sherr C.J., Weber J.D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 2000; 10 (1): 94-9.
Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999; 13 (12): 1501-12.
Nakamura M., Yonekawa Y., Kleihues P., Ohgaki H. Promoter hypermethylation of the RB1 gene in glioblastomas. Lab. Invest. 2001; 81 (1): 77-82.
Matsuura I., Denissova N.G., Wang G. et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature. 2004; 430 (6996): 226-31.
Kaminska B., Kocyk M., Kijewska M. TGF beta signaling and its role in glioma pathogenesis. Adv. Exp. Med. Biol. 2013; 986: 171-87.
Bogdahn U., Hau P., Stockhammer G. et al. Targeted therapy for high-grade glioma with the TGF-Β2 inhibitor trabedersen: results of randomized and controlled phase IIb study. Neurooncology. 2011; 13 (1): 132-42.
Ruiz i Altaba A., Sanchez P., Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer. 2002; 2 (5): 361-72.
Becher O.J., Hambardzumyan D., Fomchenko E.I. et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res. 2008; 68 (7): 2241-9.
Wang K., Pan L., Che X. et al. Sonic Hedgehog/ GLI1 signaling pathway inhibition restricts cell migration and invasion in human gliomas. Neurol. Res. 2010; 32 (9): 975-80.
Stockhausen M.T., Kristoffersen K., Poulsen H.S. The functional role of Notch signaling in human gliomas. Neurooncology. 2010; 12 (2): 199-211.
Hulleman E., Quarto M., Vernell R. et al. A role for the transcription factor HEY1 in glioblastoma. J. Cell Mol. Med. 2009; 13 (1): 136-46.
Li J.L., Sainson R.C., Shi W. et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007; 67 (23): 11244-53.
Fan X., Matsui W., Khaki L. et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006; 66 (15): 7445-52.
Ille F., Sommer L. Wnt signaling: multiple functions in neural development. Cell Mol. Life Sci. 2005; 6 (1): 6-7.
Gorze S., Wolter M., Reifenberger G. et al. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int. J. Cancer. 2010; 126 (11): 2584-93.
Pu P., Zhang Z., Kang C. et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009; 16 (4): 351-61.
Haybaeck J., Obrist P., Schindler C.U. et al. STAT-1 expression in human glioblastoma and peritumoral tissue. Anticancer Res. 2007; 27 (6B): 3829-35.
Duarte C.W., Willey C.D., Zhi D. et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One. 2012; 7 (1): e29653.
Jenkins R.B., Wrensch M.R., Johnson D. et al. Distinct germ line polimorphisms underlie glioma morphologic heterogeneity. Cancer Genet. 2011; 204 (1): 13-8.
Noushmehr H., Weisenberger D.J., Diefes K. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17 (5): 510-22.
Reitman Z.J., Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 2010; 102 (13): 932-41.
Yan H., Parsons D.W., Jin G. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 2009; 360 (8): 765-73.
Dang L., White D.W., Gross S. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462 (7274): 739-44.
Van den Bent M.J., Dubbink H.J., Marie Y. et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 2010; 16 (5): 1597-604.
Hegi M.E., Diserens A.C., Gorlia T. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005; 352 (10): 997-1003.
Rivera A.L., Pelloski C.E., Gilbert M.R. et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neurooncology. 2010; 12 (2): 116-21.
Nakamura M., Watanabe T., Yonekawa Y. et al. Promoter hypermethylation of DNA repaie gene MGMT in astrocytomas is frequently associated with G:C⇒A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis. 2001; 22 (10): 1715-9.
Vitucci M., Hayes D.N., Miller C.R. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalized therapy. Br. J. Cancer. 2011; 104 (4): 545-53.
Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K. WHO Classification of tumours of the central nervous system. Lyon: IARC; 2007.
Rickman D.S., Bobek M.P., Misek D.E. et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001; 61 (18): 6885-91.
Shirahata M., Iwao-Koizumi K., Saito S. et al. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin. Cancer Res. 2007; 13 (24): 7341-56.
Tso C.L., Freije W.A., Day A. et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006; 66 (1): 159-67.
Faury D., Nantel A., Dunn S.E. et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J. Clin. Oncol. 2007; 25 (10): 1196-208.
Freije W.A., Castro-Vargas F.E., Fang Z. et al. Gene expression profiling of gliomas strongly predicts survival. Cancer res. 2004; 64 (18): 6503-10.
Phillips H.S., Kharbanda S., Chen R. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9 (3): 157-73.
Li A., Walling J., Ahn S. et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 2009; 69 (5): 2091-9.
Verhaak R.G., Hoadley K.A., Purdom E. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17 (1): 98-110.
Idbaih A., Dalmasso C., Kouwenhoven M. et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J. Neurooncol. 2011; 103 (2): 221-30.
Nutt C.L. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. Neurosurg. Focus. 2005; 19: E2.
Hegi M.E., Janzer R.C., Lambiv W.L. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathlogy review of the EORTC 26981/NCIC CE.3 trial. Acta Neuropathol. 2012; 123 (6): 841-52.
Boerman R.H., Anderl K., Herath J. et al. The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. J. Neuropathol. Exp. Neurol. 1996; 55 (9): 973-81.
Martinez R., Rohde V., Schackert G. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J. Neurooncol. 2010; 96 (3): 321-9.

Close metadata